Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B CAR-T Cell Therapy in SLE or SSc
NCT06822881Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-1190B in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), sponsored by Beijing Gaobo Hospital. Primary endpoint: Dose Limiting Toxicity, Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 12 months. Started Feb 2025; status: recruiting.
02
Drugs
CT-1190B
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06822881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822881.